media – Page 19 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Fuyuan Pharmaceutical’s Ketoprofen Patch Approved for Clinical Trial

On June 5, Fuyuan Pharmaceutical announced that it had recently received the “Drug Clinical Trial Approval Notice” for Ketoprofen Patch approved and issued by the State Drug Administration. The drug’s indications include a variety of pain and inflammation-related diseases, such as low back pain, osteoarthritis and rheumatoid arthritis. Ketoprofen patches have been approved in countries or regions such as Japan, Italy, and Portugal, but as of June 2025, no manufacturer has imported them for sale. According to data from MinEnet, the sales of ketoprofen patches in the Chinese market in 2024 will be about 5 million yuan, of which sales in urban public hospitals and county-level public hospitals will be 2.33 million yuan, and sales in urban physical pharmacies and online pharmacies will be 2.67 million yuan. The product still needs to go through the relevant approval procedures before it can be launched, and there is still uncertainty as to ...
- Source: drugdu
- 71
- June 9, 2025
The medical price and procurement credit evaluation system will be further improved to increase the punishment for dishonest behavior.

In order to guide enterprises to operate with integrity and compliance and further promote the healthy development of the centralized pharmaceutical procurement market, the National Healthcare Security Administration recently issued the “Notice on Further Improving the Pharmaceutical Price and Procurement Credit Evaluation System” to revise the pharmaceutical price and procurement credit evaluation system. In August 2020, the National Healthcare Security Administration issued the Guiding Opinions on Establishing a Credit Evaluation System for Pharmaceutical Prices and Procurement, and carried out credit rating, graded disposal, credit repair and other work based on the facts of cases such as drug sales with money and bid rigging determined by court judgments or administrative penalties. By the end of 2024, 735 untrustworthy enterprises were assessed, including 7 “particularly serious” untrustworthy enterprises, 40 “serious” untrustworthy enterprises, 76 “medium” untrustworthy enterprises, and 612 “general” untrustworthy enterprises. The implementation of this system has played a positive role in ...
- Source: drugdu
- 54
- June 9, 2025
【EXPERT Q&A】What is the difference between siRNA and shRNA? How should the grouping for regular interference detection be set?

Drugdu.com expert’s response: I. Differences Between siRNA and shRNA 1. Structure and Composition siRNA (Small Interfering RNA): siRNA is a double-stranded RNA molecule, typically 20-25 base pairs in length, with a 2-nucleotide 3′ overhang at both ends. It consists of two complementary RNA strands: a sense strand (homologous to the target mRNA) and an antisense strand (complementary to the target mRNA). siRNA is usually generated from exogenous or endogenous double-stranded RNA through cleavage by the Dicer enzyme. shRNA (Short Hairpin RNA): shRNA is a single-stranded RNA capable of forming a hairpin (stem-loop) structure, comprising a short double-stranded region (19-29 bp) and a loop region. It consists of a sense strand, a loop sequence, and an antisense strand, forming a hairpin shape. shRNA is constructed into expression vectors through genetic engineering techniques and forms a hairpin structure upon transcription. 2. Mechanism of Action siRNA: After being cleaved by the Dicer enzyme, siRNA directly binds ...
- Source: drugdu
- 108
- June 9, 2025
Proinflammatory Foods Tied to Higher Risk of Death in Colon Cancer Patients

WEDNESDAY, June 4, 2025 (HealthDay News) — What you eat after a colon cancer diagnosis could do more than affect your energy or digestion — it might impact your chance of survival. Researchers looked at more than 1,600 patients with stage 3 colon cancer. They found that those who ate the most proinflammatory foods had an 87% higher risk of death compared to those who ate the least. These foods may cause an inflammatory response such swelling or irritation in the body. Over time, this type of chronic inflammation is linked to many diseases, including cancer, The Independent of London reported. “One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,” said lead author Dr. Sara Char, a clinical fellow at Dana-Farber Cancer Institute in Boston. “These findings add to the published literature ...
- Source: drugdu
- 81
- June 6, 2025
Wayne State researchers investigate effects of fentanyl use during pregnancy

A new National Institutes of Health (NIH) grant will aid Wayne State University researchers in measuring the effects of fentanyl during pregnancy on maternal behaviors and offspring at birth through early development. This two-year, $423,500 grant, “Understanding the effects of gestational fentanyl exposure on external morphology, neonatal opioid withdrawal, and brain volume, morphology and neurochemistry of offspring,” is supported by the National Institute on Drug Abuse of the NIH. The principal investigators on this study are Shane Perrine, Ph.D., associate professor of psychiatry and behavioral neurosciences in Wayne State’s School of Medicine, and Susanne Brummelte, Ph.D., professor of psychology in Wayne State’s College of Liberal Arts and Sciences. “Our labs have collaborated on prior studies and this project is a natural extension of our previous work. I was working on the study of illicit fentanyl use and Susie’s lab was looking at the effects of opioids, including morphine and buprenorphine, ...
- Source: drugdu
- 74
- June 6, 2025
The second new drug application for the combination of Xindilimumab and Fruquintinib has been accepted by the National Medical Products Administration

On June 5th, Xinda Biotechnology and Hehuang Pharmaceutical jointly announced that the new drug application for the combination therapy of Xindilimumab and Fruquintinib for the treatment of locally advanced or metastatic renal cell carcinoma patients who have previously failed treatment with a tyrosine kinase inhibitor has been accepted by the National Medical Products Administration (NMPA) of China. It is reported that the combination therapy of xindilimab and furosemide obtained conditional approval from NMPA in December 2024 for the treatment of advanced mismatch repair intact (pMMR) endometrial cancer patients who have failed previous systemic anti-tumor therapy and are not suitable for radical surgery or radiotherapy.
- Source: drugdu
- 87
- June 6, 2025
BCHT’s recombinant shingles vaccine clinical trial application approved

On the evening of June 4, BCHT, the company announced that it had received the “Notice of Approval for Drug Clinical Trial” for the recombinant herpes zoster vaccine (CHO cells) issued by the National Medical Products Administration, and the conclusion was that it agreed to conduct clinical trials for the prevention of herpes zoster. Herpes zoster is an acute infectious skin disease caused by the reactivation of the varicella-zoster virus (VZV) lurking in the body. The recombinant herpes zoster vaccine (CHO cells) approved for clinical use by Biotech is for adults aged 40 and above. After vaccination, it can stimulate the body to produce immunity against the varicella-zoster virus and is used to prevent herpes zoster. According to reports, the recombinant shingles vaccine (CHO cells) developed by the company is based on varicella-zoster virus glycoprotein E (gE protein) and is combined with the company’s independently developed innovative BK-02 adjuvant system. ...
- Source: drugdu
- 76
- June 6, 2025
Nine-valent HPV vaccine approved for marketing

On the evening of June 4, Wantai BioThe company announced that the nine-valent human papillomavirus (HPV) vaccine (Escherichia coli) (trade name: Xinkening 9) jointly developed by the company’s wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. (“Wantai Vaccine”) and Xiamen University has been approved for marketing by the National Medical Products Administration. Previously, there was only one nine-valent HPV vaccine on the market worldwide, which was developed by MerckGardasil® 9. Wantai Vaccine, located in Xiamen Biomedicine Port, has worked closely with the National Infectious Disease Diagnostic Reagent and Vaccine Engineering Technology Research Center (NIDVD) of Xiamen University to build a mature industry-university-research model. The two parties have developed and launched a number of innovative vaccines, from hepatitis E vaccine, bivalent HPV vaccine, to the current nine-valent HPV vaccine (Xinkening 9). The launch of Xinkening 9 is the result of 18 years of collaborative innovation in “industry-university-research” between the two parties. ...
- Source: drugdu
- 104
- June 6, 2025
Breakthrough in Alzheimer’s disease diagnosis and treatment

Alzheimer’s disease (AD) is a disease that scares countless families. It has an insidious onset, continues to progress, and is irreversible. Brain lesions have already occurred quietly 15 to 20 years before obvious symptoms appear. Moving the diagnosis and intervention window forward is a key measure to reduce the incidence of AD. In decades of exploration, existing drugs have always been trapped in the cage of “delaying symptoms”. Now, with the maturity of diagnostic technology and the emergence of a new generation of drugs targeting beta-amyloid protein (Aβ), the academic community sees hope of “pressing the pause button on the disease”. In 2021, Aducanumab received accelerated approval from the FDA, becoming the first new drug approved by the FDA for AD, for the treatment of AD-related mild cognitive impairment (MCI) and mild AD. In 2023, the FDA approved Lecanemab for the treatment of early AD with mild cognitive impairment or ...
- Source: drugdu
- 68
- June 6, 2025
After Apixaban! Who will be the next anticoagulant king?

Among the bright stars of antithrombotic drugs, there are two dazzling stars that must be mentioned. One is aspirin, which is known as the “world’s best-selling drug”. The annual global consumption is still over 100 billion tablets, which can circle the earth 25 times if they are lined up; the other is apixaban, which has continuously broken through sales since its launch and firmly sits at the top of the small molecule drug sales list. As a key drug category in the field of cardiovascular disease treatment, antithrombotic drugs firmly occupy the top position both in the global drug sales rankings and in the actual needs of clinical treatment. They are an indispensable “weapon” for the treatment of cardiovascular diseases. Nowadays, as the global population aging trend becomes more and more obvious, the number of patients with cardiovascular diseases continues to rise. At the same time, the steady improvement of ...
- Source: drugdu
- 91
- June 6, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.